Targeting the mitogen-activated protein kinase pathway: physiological feedback and drug response

Por Pratilas, Christine A., Solit, David B.
Publicado em 2010

TARGETING ONCOGENIC BRAF IN HUMAN CANCER

Por Pratilas, Christine, Xing, Feng, Solit, David
Publicado em 2012

Targeted therapy for soft tissue sarcomas in adolescents and young adults

Por Steppan, Diana A, Pratilas, Christine A, Loeb, David M
Publicado no Adolesc Health Med Ther (2017)

Dermatologic adverse events in pediatric patients receiving targeted anticancer therapies: a pooled analysis

Por Belum, Viswanath Reddy, Washington, Courtney, Pratilas, Christine A., Sibaud, Vincent, Boralevi, Franck, Lacouture, Mario E.
Publicado no Pediatr Blood Cancer (2015)

(V600E)BRAF is associated with disabled feedback inhibition of RAF–MEK signaling and elevated transcriptional output of the pathway

Por Pratilas, Christine A., Taylor, Barry S., Ye, Qing, Viale, Agnes, Sander, Chris, Solit, David B., Rosen, Neal
Publicado em 2009

Ifosfamide Dose-Intensification for Patients with Metastatic Ewing Sarcoma

Por Magnan, Heather, Goodbody, Christine M., Riedel, Elyn, Pratilas, Christine A., Wexler, Leonard H., Chou, Alexander J.
Publicado no Pediatr Blood Cancer (2015)

Models from experiments: combinatorial drug perturbations of cancer cells

Por Nelander, Sven, Wang, Weiqing, Nilsson, Björn, She, Qing-Bai, Pratilas, Christine, Rosen, Neal, Gennemark, Peter, Sander, Chris
Publicado em 2008

Identification of unique MEK-dependent genes in GNAQ mutant uveal melanoma involved in cell growth, tumor cell invasion and MEK-resistance.

Por Ambrosini, Grazia, Pratilas, Christine A., Qin, Li-Xuan, Tadi, Madhavi, Surriga, Oliver, Carvajal, Richard D., Schwartz, Gary K.
Publicado em 2012

BRAF(V600E) Mutation Is Associated with Preferential Sensitivity to Mitogen-Activated Protein Kinase Kinase Inhibition in Thyroid Cancer Cell Lines

Por Leboeuf, Rebecca, Baumgartner, Jacqueline E., Benezra, Miriam, Malaguarnera, Roberta, Solit, David, Pratilas, Christine A., Rosen, Neal, Knauf, Jeffrey A., Fagin, James A.
Publicado em 2008

3′-Deoxy-3′-[(18)F]Fluorothymidine Positron Emission Tomography Is a Sensitive Method for Imaging the Response of BRAF-Dependent Tumors to MEK Inhibition

Por Solit, David B., Santos, Elmer, Pratilas, Christine A., Lobo, Jose, Moroz, Maxim, Cai, Shangde, Blasberg, Ronald, Sebolt-Leopold, Judith, Larson, Steven, Rosen, Neal
Publicado em 2007

Interferon α/β enhances the cytotoxic response of MEK inhibition in melanoma

Por Litvin, Oren, Schwartz, Sarit, Wan, Zhenmao, Schild, Tanya, Rocco, Mark, Oh, Nul Loren, Chen, Bo-Juen, Goddard, Noel, Pratilas, Christine, Pe’er, Dana
Publicado no Mol Cell (2015)

Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR mutant Lung Cancer

Por Tricker, Erin M., Xu, Chunxiao, Uddin, Sharmeen, Capelletti, Marzia, Ercan, Dalia, Ogino, Atsuko, Pratilas, Christine A., Rosen, Neal, Gray, Nathanael S., Wong, Kwok-Kin, Jänne, Pasi A.
Publicado no Cancer Discov (2015)

Perturbation biology nominates upstream–downstream drug combinations in RAF inhibitor resistant melanoma cells

Por Korkut, Anil, Wang, Weiqing, Demir, Emek, Aksoy, Bülent Arman, Jing, Xiaohong, Molinelli, Evan J, Babur, Özgün, Bemis, Debra L, Onur Sumer, Selcuk, Solit, David B, Pratilas, Christine A, Sander, Chris
Publicado no eLife (2015)

Size-based detection of sarcoma circulating tumor cells and cell clusters

Por Hayashi, Masanori, Zhu, Peixuan, McCarty, Gregory, Meyer, Christian F., Pratilas, Christine A., Levin, Adam, Morris, Carol D., Albert, Catherine M., Jackson, Kyle W., Tang, Cha-Mei, Loeb, David M.
Publicado no Oncotarget (2017)

The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner

Por Joseph, Eric W., Pratilas, Christine A., Poulikakos, Poulikos I., Tadi, Madhavi, Wang, Weiqing, Taylor, Barry S., Halilovic, Ensar, Persaud, Yogindra, Xing, Feng, Viale, Agnes, Tsai, James, Chapman, Paul B., Bollag, Gideon, Solit, David B., Rosen, Neal
Publicado em 2010

BRAF mutation predicts sensitivity to MEK inhibition

Por Solit, David B., Garraway, Levi A., Pratilas, Christine A., Sawai, Ayana, Getz, Gad, Basso, Andrea, Ye, Qing, Lobo, Jose M., She, Yuhong, Osman, Iman, Golub, Todd R., Sebolt-Leopold, Judith, Sellers, William R., Rosen, Neal
Publicado em 2005

Genetic predictors of MEK-dependence in non-small cell lung cancer

Por Pratilas, Christine A., Hanrahan, Aphrothiti J., Halilovic, Ensar, Persaud, Yogindra, Soh, Junichi, Chitale, Dhananjay, Shigematsu, Hisayuki, Yamamoto, Hiromasa, Sawai, Ayana, Janakiraman, Manickam, Taylor, Barry S., Pao, William, Toyooka, Shinichi, Ladanyi, Marc, Gazdar, Adi, Rosen, Neal, Solit, David B.
Publicado em 2008

Perturbation Biology: Inferring Signaling Networks in Cellular Systems

Por Molinelli, Evan J., Korkut, Anil, Wang, Weiqing, Miller, Martin L., Gauthier, Nicholas P., Jing, Xiaohong, Kaushik, Poorvi, He, Qin, Mills, Gordon, Solit, David B., Pratilas, Christine A., Weigt, Martin, Braunstein, Alfredo, Pagnani, Andrea, Zecchina, Riccardo, Sander, Chris
Publicado em 2013

Paradoxical activation of T cells via augmented ERK signaling mediated by a RAF inhibitor

Por Callahan, Margaret K., Masters, Gregg, Pratilas, Christine A., Ariyan, Charlotte, Katz, Jessica, Kitano, Shigehisa, Russell, Valerie, Gordon, Ruth Ann, Vyas, Shachi, Yuan, Jianda, Gupta, Ashok, Wigginton, Jon M., Rosen, Neal, Merghoub, Taha, Jure-Kunkel, Maria, Wolchok, Jedd D.
Publicado em 2013

RELIEF OF PROFOUND FEEDBACK INHIBITION OF MITOGENIC SIGNALING BY RAF INHIBITORS ATTENUATES THEIR ACTIVITY IN BRAFV600E MELANOMAS

Por Lito, Piro, Pratilas, Christine A., Joseph, Eric W., Tadi, Madhavi, Halilovic, Ensar, Zubrowski, Matthew, Huang, Alan, Wong, Wai Lin, Callahan, Margaret K., Merghoub, Taha, Wolchok, Jedd D., de Stanchina, Elisa, Chandarlapaty, Sarat, Poulikakos, Poulikos I., Fagin, James A., Rosen, Neal
Publicado em 2012